GUARDIAN Registry data presented at ISHLT 2022 has shown a 72% reduction (p=0.005) in Severe PGD (primary graft dysfunction) and a 39% reduction (p=0.03) in Mechanical Circulatory Support, in addition to improvement in 1-year survival1,2 CAMBRIDGE, Mass.–(BUSINESS WIRE)–Paragonix Technologies, Inc., a leading organ preservation provider, announces today groundbreaking research from […]
Other News
Conavi Medical’s Novasight Hybrid System Now In Use at Sunnybrook Health Sciences Centre
Sunnybrook’s Schulich Heart Program to provide the latest innovative hybrid imaging of coronary arteries for complex cases TORONTO–(BUSINESS WIRE)–Conavi Medical Inc. (www.conavi.com), a leader of hybrid imaging guidance for common minimally invasive heart procedures, and Sunnybrook Health Sciences Centre, today announced that the Novasight Hybrid System is now being used […]
Vektor Medical to Present Positive Results from vMap Clinical Validation Study Showing 97.3% Mapping Accuracy for Atrial and Ventricular Arrhythmias
SAN FRANCISCO–(BUSINESS WIRE)–Vektor Medical today announced positive results from its “Vektor vMap™ Clinical Validation Study” evaluating the accuracy of cardiac mapping with vMap™. The study achieved statistically significant results of 98.7% in accurately identifying the regional arrhythmia source location for premature ventricular complex (PVC) and ventricular tachycardia (VT), 96.9% in accurately […]
Alnylam Pharmaceuticals Reports First Quarter 2022 Financial Results and Highlights Recent Period Activity
− Achieved First Quarter 2022 Global Net Product Revenues of $187 Million for ONPATTRO®, GIVLAARI®, and OXLUMO® – − Reported Positive 18-Month Results from HELIOS-A Phase 3 Study of Vutrisiran in hATTR Amyloidosis Patients with Polyneuropathy – − Announced 3-Month Extension of Review Period for New Drug Application for Vutrisiran due […]
Baxter Reports First-Quarter 2022 Results
First-quarter revenue of $3.7 billion increased 26% on a reported basis, 29% on a constant currency basis and 3% on an operational basis1 First-quarter U.S. GAAP earnings per share (EPS) totaled $0.14; Adjusted EPS totaled $0.93 Baxter expects full-year 2022 sales growth of 23% to 24% on a reported basis, […]
Abiomed Announces Fourth Quarter Record Revenue of $270 Million, up 12% Year Over Year
FY 2022 Annual Revenue of $1.032 billion, Up 22% Versus Prior Year DANVERS, Mass.–(BUSINESS WIRE)–ABIOMED, Inc. (NASDAQ: ABMD), a leader in breakthrough heart, lung and kidney support technologies, today announced financial results for the quarter and fiscal year ended March 31, 2022. Financial summary and operational highlights: Revenue for the […]
Acutus Medical Announces Agreements to Fund Strategic Growth Priorities
CARLSBAD, Calif., April 27, 2022 (GLOBE NEWSWIRE) — Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced a commitment letter from Deerfield Management Company (“Deerfield”), to refinance its existing debt with a new […]
BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR FIRST QUARTER 2022
MARLBOROUGH, Mass., April 27, 2022 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.026 billion during the first quarter of 2022, growing 10.0 percent on a reported basis, 12.6 percent on an operational1 basis and 9.7 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income […]
EDWARDS LIFESCIENCES REPORTS FIRST QUARTER RESULTS
IRVINE, Calif., April 26, 2022 /PRNewswire/ — Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended March 31, 2022. First Quarter Highlights and Outlook Q1 sales grew 10 percent to $1.34 billion; underlying1 13 percent Q1 TAVR sales grew 11 percent; underlying 14 percent Q1 EPS was $0.59; adjusted1 EPS was $0.60 Full year 2022 financial […]
AMGEN ANNOUNCES RESULTS FROM TWO OPEN LABEL EXTENSION STUDIES OF REPATHA® (EVOLOCUMAB)
Studies Showed Sustained Reduction in LDL-C With no new Safety Findings The Combined Studies Evaluated Safety and Tolerability of Repatha in More Than 6,600 Patients for Over Five Years After Completing the Phase 3 FOURIER Trial Repatha is the Longest Studied PCSK9i THOUSAND OAKS, Calif., April 27, 2022 /PRNewswire/ — Amgen (NASDAQ:AMGN) […]



